stockportfolio.pro
Stocks / CTMX vs DSGN
CTMX vs DSGN
CytomX Therapeutics, Inc. and Design Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| CytomX Therapeutics, Inc. (CTMX) | Design Therapeutics, Inc. (DSGN) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $76.20M | $0 |
| Net income (latest FY) | $-17.37M | $-69.79M |
| Revenue growth (5y CAGR) | 2.2% | — |
| Net margin | -22.8% | — |
| Return on equity | -17.5% | -32.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CTMX — free Open DSGN — freeFrequently asked questions
Which is bigger, CTMX or DSGN?
Design Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, CTMX or DSGN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.